Edward V. Kogan

Edward V. Kogan

Auto-generated profile, based on publicly available information

Edward V. Kogan

Department of Medicine, Division of Cardiology, Weill Cornell Medicine—New York Presbyterian Hospital and Weill Cornell Cardiovascular Outcomes Research Group (CORG) , 520 East 70th Street 4th Floor, New York, NY 10021

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in The American Journal of Cardiology
Verified
Journal Article
Closed access
ECEhud Chorin
Ehud Chorin
CPConnor Peterson
Connor Peterson
EKEdward Kogan
Edward Kogan
CBChirag Barbhaiya
Chirag Barbhaiya
AAAnthony Aizer
Anthony Aizer
LJLior Jankelson
Lior Jankelson

1 April 2023 in Stroke
Verified
Journal Article
Closed access
EKEdward V. Kogan
Edward V. Kogan
CSChristopher T. Sciria
Christopher T. Sciria
CLChristopher Liu
Christopher Liu
SWShing Chiu Wong
Shing Chiu Wong
GBGeoffrey Bergman
Geoffrey Bergman
JCJim W. Cheung
Jim W. Cheung
Background: Percutaneous endocardial left atrial appendage occlusion (LAAO) is an alternative therapy for stroke prevention in patients with atrial fibrillation who are poor candidates for oral anticoagulants. Oral anticoagulation is generally discontinued 45 days following successful LAAO. Real-world data on early stroke and mortality following LAAO are lacking. Methods: Using International Classification of Diseases, Tenth Revision , Clinical-Modification codes, we performed a retrospective observational registry analysis to examine the rates and predictors of stroke, mortality, and procedural complications during index hospitalization and 90-day readmission among 42 114 admissions in the Nationwide Readmissions Database for LAAO between 2016 and 2019. Early stroke and mortality were defined as events occurring during index admission or 90-day readmission. Data on timing of early strokes post-LAAO were collected. Multivariable logistic regression modeling was used to ascertain predictors of early stroke and major adverse events. Results: LAAO was associated with low rates of early stroke (0.63%), early mortality (0.53%), and procedural complications (2.59%). Among patients who had readmissions with strokes after LAAO, the median time from implant to readmission was 35 days (interquartile range, 9–57 days); 67% of readmissions with strokes occurred <45 days postimplant. Between 2016 and 2019, the rates of early stroke after LAAO significantly decreased (0.64% versus 0.46% P -for-trend <0.001), while early mortality and major adverse event rates were unchanged. Peripheral vascular disease and a history of prior stroke were independently associated with early stroke after LAAO. Early post-LAAO stroke rates were similar between low, medium, and high LAAO volume tertile centers. Conclusions: In this contemporary real-world analysis, the early stroke rate after LAAO was low, with the majority occurring within 45 days of device implantation. Despite an increase in LAAO procedures between 2016 and 2019, there with a significant decline in early strokes after LAAO during that period.

26 December 2024 in EP Europace
Verified
Journal Article
Open access
AMAri G Mandler
Ari G Mandler
CSChristopher T Sciria
Christopher T Sciria
EKEdward V Kogan
Edward V Kogan
IKIlya Kim
Ilya Kim
IYIlhwan Yeo
Ilhwan Yeo
JCJim W Cheung
Jim W Cheung
Aims: Utilization of transvenous lead extraction/removal (TLE) for the management of cardiac implantable electronic device (CIED)-associated infective endocarditis (IE) remains low. The aim of this study was to examine the impact of hospital TLE procedural volume on TLE utilization and outcomes for patients with CIED-associated IE. Methods and results: Using the Nationwide Readmissions Database, we evaluated 21 545 admissions for patients (mean age 70 years, 39% female) with CIEDs hospitalized with IE at TLE centres. Hospitals were categorized based on annual volume tertiles: (i) low-volume (1–17 TLEs/year), (ii) medium-volume (18–45 TLEs/year), and (iii) high-volume centres (>45 TLEs/year). Between 2016 and 2019, 57% of admissions in the study were to low-volume TLE centres. Transvenous lead extraction/removal was performed during 6.9, 19.3, and 26% of admissions for CIED-associated IE at low-, medium-, and high-volume TLE centres, respectively (P < 0.001). After adjustment for age and comorbidities, hospitalization for IE at high-volume centres was independently associated with TLE when compared with low-volume centres (adjusted odds ratio 4.26; 95% confidence interval 3.53–5.15). Transvenous lead extraction/removal-associated complication rates were similar at 2.5, 2.3, and 3.4% at low-, medium-, and high-volume centres, respectively (P = 0.493). Overall inpatient mortality during admissions to low-, medium-, and high-volume centres was also similar. Conclusion: Admissions to high-volume TLE centres were associated with higher utilization of TLE for management of CIED-associated IE. Transvenous lead extraction/removal-associated complications and mortality among patients hospitalized with CIED-associated IE were similar when stratified by hospital TLE volume, but this needs to be considered in context of significant differences in patient comorbidity burden between centres.